Arrowhead Pharmaceuticals (ARWR) Change in Account Payables (2010 - 2026)

Arrowhead Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• Quarterly Change in Account Payables rose 54.24% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.1 million (up 1734.29% YoY) and the FY2025 annual result came in at $6.3 million, up 213.55% from the prior year.
• Change in Account Payables was -$2.2 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $15.3 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $28.0 million in Q3 2023 and bottomed at -$15.4 million in Q3 2025.
• A 5-year average of $2.7 million and a median of -$1.7 million in 2023 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables soared 1284.53% — and 2023, when it slumped 501.5%.
• Arrowhead Pharmaceuticals' Change in Account Payables stood at -$2.1 million in 2022, then slumped by 501.5% to -$12.5 million in 2023, then jumped by 124.62% to $3.1 million in 2024, then jumped by 397.33% to $15.3 million in 2025, then sank by 114.35% to -$2.2 million in 2026.
• Business Quant data shows ARWR's Change in Account Payables at -$2.2 million in Q1 2026, $15.3 million in Q4 2025, and -$15.4 million in Q3 2025.